DownRightNowNews
Trending
The overlooked argument that could doom Trump’s media banBandas exteriores de lluvia del huracán Polo llegan a la costa de MéxicoChild-care programs reopening after staffing shortage on Sunshine CoastMajor row after Macron says Hamas has ‘never been active’ in West BankThe overlooked argument that could doom Trump’s media banBandas exteriores de lluvia del huracán Polo llegan a la costa de MéxicoChild-care programs reopening after staffing shortage on Sunshine CoastMajor row after Macron says Hamas has ‘never been active’ in West Bank
Health

Cellares and Seoul National University Hospital Launch Proof-of-Concept for Automated Manufacturing of Gene-Modified HSPC Therapy on the Cell Shuttle® Platform

·1h ago
Share:PostShare

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and Seoul National University Hospital (SNUH), a leading translational medical center in South Korea, today announced a partnership to evaluate automated manufacturing for a gene-modified hematopoietic stem and progenitor cell (HSPC) therapy targeting paroxysmal nocturnal hemoglobinuria (PNH) on Cellares’ Cell Shuttle platform. The collaboration will evaluate the trans

B

Businesswire

Original source

Read full story
EducationCrimeGovernment

Related Stories

Health1h ago

Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA

LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present and moderate a discussion in person at the 24th Annual Discovery on Target Drug Discovery Conference. The conference is being held on Sept. 28 to Oct. 1 at the Sheraton Boston Hotel with sessions available on demand on the conference’s website. Bhow

BBusinesswire
Health7h ago

Cancer-related DNA changes may appear in blood years before diagnosis

Researchers found that genome-wide plasma cfDNA methylation profiles collected before diagnosis contained early molecular signatures associated with future prostate and breast cancer, with prostate silencer methylation providing the stronger risk stratification. Breast enhancer signals were weaker and varied by subtype and disease stage, indicating that cfDNA methylation may have greater value for risk assessment and surveillance than as a standalone diagnostic test.

MMedical News

Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.

Read Disclaimer